デブリソキン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/10/09 06:57:41」(JST)
[Wiki en表示]
Debrisoquine[1] |
|
IUPAC name
1,2,3,4-tetrahydroisoquinoline-2-carboximidamide
|
Identifiers |
CAS number |
1131-64-2 Y |
PubChem |
2966 |
ChemSpider |
2860 Y |
UNII |
X31CDK040E Y |
DrugBank |
DB04840 |
KEGG |
C13650 Y |
MeSH |
Debrisoquine |
ChEBI |
CHEBI:34665 Y |
ChEMBL |
CHEMBL169901 Y |
ATC code |
C02CC04 |
Jmol-3D images |
Image 1 |
-
[N@H]=C(N)N2Cc1c(cccc1)CC2
|
-
InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12) Y
Key: JWPGJSVJDAJRLW-UHFFFAOYSA-N Y
InChI=1/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
Key: JWPGJSVJDAJRLW-UHFFFAOYAE
|
Properties |
Molecular formula |
C10H13N3 |
Molar mass |
175.23032 |
Y (verify) (what is: Y/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
Infobox references |
Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug metabolizing enzyme.[2]
See also[edit]
- Isoquinoline#Applications of derivatives
References[edit]
- ^ Debrisoquine - Compound Summary, PubChem.
- ^ Fuhr, U.; Jetter, A.; Kirchheiner, J. (2007). "Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach". Clinical Pharmacology & Therapeutics 81 (2): 270. doi:10.1038/sj.clpt.6100050. edit
Sympatholytic (and closely related) antihypertensives (C02)
|
|
Sympatholytics
(antagonize α-adrenergic
vasoconstriction) |
Central
|
α2 agonist
|
- Clonidine
- Guanfacine
- Methyldopa #
|
|
Adrenergic release inhibitors
|
- Bethanidine
- Bretylium
- Debrisoquine
- Guanadrel
- Guanazodine
- Guanethidine
- Guanoclor
- Guanoxan
- Guanazodine
- Guanoxabenz
- Guanoxan
|
|
Imidazoline receptor agonist
|
|
|
Ganglion-blocking/nicotinic antagonist
|
- Mecamylamine
- Pentolinium
- Trimethaphan
|
|
|
Peripheral
|
Indirect
|
MAOI
|
|
|
Adrenergic uptake inhibitor
|
- Bietaserpine
- Deserpidine
- Methoserpidine
- Rescinnamine
- Reserpine
|
|
Tyrosine hydroxylase inhibitor
|
|
|
|
Direct
|
α1 blockers
|
- Prazosin
- Indoramin
- Trimazosin
- Doxazosin
- Urapidil
|
|
Non-selective α blocker
|
|
|
|
|
|
Other antagonists |
Serotonin antagonist
|
|
|
Endothelin antagonist (for PH)
|
- dual (Bosentan)
- selective (Ambrisentan, Sitaxentan)
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
anat (a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
|
noco/syva/cong/lyvd/tumr, sysi/epon, injr
|
proc, drug (C2s+n/3/4/5/7/8/9)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Inhibition of peripheral dopamine metabolism and the ventilatory response to hypoxia in the rat.
- Bialkowska M1, Zajac D, Mazzatenta A, Di Giulio C, Pokorski M.
- Advances in experimental medicine and biology.Adv Exp Med Biol.2015;837:9-17. doi: 10.1007/5584_2014_72.
- Dopamine (DA) is a putative neurotransmitter in the carotid body engaged in the generation of the hypoxic ventilatory response (HVR). However, the action of endogenous DA is unsettled. This study seeks to determine the ventilatory effects of increased availability of endogenous DA caused by inhibiti
- PMID 25310955
- Time- and NADPH-dependent inhibition of cytochrome P450 3A4 by the cyclopentapeptide cilengitide: significance of the guanidine group and accompanying spectral changes.
- Bojić M1, Barbero L1, Dolgos H1, Freisleben A1, Gallemann D1, Riva S1, Guengerich FP2.
- Drug metabolism and disposition: the biological fate of chemicals.Drug Metab Dispos.2014 Sep;42(9):1438-46. doi: 10.1124/dmd.114.059295. Epub 2014 Jul 1.
- Cilengitide is a stable cyclic pentapeptide containing an Arg-Gly-Asp motif responsible for selective binding to αVβ3 and αVβ5 integrins. The candidate drug showed unexpected inhibition of cytochrome P450 (P450) 3A4 at high concentrations, that is, a 15-mM concentration caused attenuation of P45
- PMID 24985702
- CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
- Llerena A1, Dorado P, Ramírez R, Calzadilla LR, Peñas-Lledó E, Álvarez M, Naranjo ME, González I, Pérez B; CEIBA Consortium of Ibero–American Network of Pharmacogenetics & Pharmacogenomics RIBEF.
- Pharmacogenomics.Pharmacogenomics.2013 Dec;14(16):1973-7. doi: 10.2217/pgs.13.181.
- BACKGROUND & AIM: The CYP2D6 -1584C>G polymorphism (rs1080985) has been identified as a major factor for CYP2D6 expression and function, with the mutant -1584G promoter type being consistently associated with significantly greater expression than -1584C. It may therefore be associated with ul
- PMID 24279852
Japanese Journal
- Effect of Cyclosporine and Tacrolimus on Cytochrome P450 Activities in Human Liver Microsomes
- 丹羽 俊朗,山本 幸子,斎藤 美穂 [他],白神 歳文,高木 明
- 藥學雜誌 127(1), 209-216, 2007-01-01
- … The effects of cyclosporine and tacrolimus on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2C9-mediated tolbutamide hydroxylation, CYP2C19-mediated S-mephenytoin 4'-hydroxylation, CYP2D6-mediated debrisoquine 4-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, CYP3A4-mediated nifedipine oxidation, and CYP3A4-mediated testosterone 6β-hydroxylation activities in human liver microsomes were compared. …
- NAID 110006155027
- Effects of Serotonin-3 Receptor Antagonists on Cytochrome P450 Activities in Human Liver Microsomes(Biopharmacy)
- Niwa Toshiro,Yamamoto Sachiko,Saito Miho [他],KOBAYASHI Naoto,IKEDA Kaoru,NODA Yasuo,TAKAGI Akira
- Biological & pharmaceutical bulletin 29(9), 1931-1935, 2006-09-01
- … The effects of three serotonin-3 (5-HT_3) receptor antagonists, azasetron, ondansetron, and ramosetron, on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2C9-mediated tolbutamide hydroxylation, CYP2C19-mediated S-mephenytoin 4'-hydroxylation, CYP2D6-mediated debrisoquine 4-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, CYP3A4-mediated nifedipine oxidation, and CYP3A4-mediated testosterone 6β-hydroxylation activities in human liver microsomes were compared. …
- NAID 110005602364
- Effect of Antifungal Drugs on Cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 Activities in Human Liver Microsomes(Biopharmacy)
- Niwa Toshiro,Inoue-Yamamoto Sachiko,Shiraga Toshifumi [他],TAKAGI Akira
- Biological and Pharmaceutical Bulletin 28(9), 1813-1816, 2005-09-01
- … The effects of five antifungal drugs, fluconazole, itraconazole, micafungin, miconazole, and voriconazole, on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2D6-mediated debrisoquine 4-hydroxylation, and CYP2E1-mediated chlorzoxazone 6-hydroxylation activities in human liver microsomes were compared. …
- NAID 110003666521
Related Links
- Debrisoquine is an adrenoceptor neuron blocking agent that prevents the release of norepinephrine from postganglionic adrenoceptor neurones. It was once used fo ... Targets-Pharmacodynamics Debrisoquine prevents the release of ...
- Read more about the pharmacogenomics of debrisoquine on PharmGKB. ... Debrisoquin acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting ...
Related Pictures
★リンクテーブル★
[★]
- 英
- debrisoquine、debrisoquin
- 化
- 硫酸デブリソキン debrisoquine sulphate
- 降圧薬、グアニジン誘導体、末梢性交感神経遮断。現在は使われていない。